The study presented by Mary-Ellen Taplin, MD, and colleagues found that the addition of abiraterone during 6 months of hormonal therapy prior to surgery eliminated or nearly eliminated tumors in one-third of men with localized high-risk prostate cancer. Here, Donald L. Trump, MD, reviews the implications of these results.